CRBN and diffuse large B-cell lymphoma: In comparison, previously discovered CRBN-based heterobifunctional BCL6 degraders did not achieve complete BCL6 degradation and failed to induce a significant phenotypic response in diffuse large B-cell lymphoma (DLBCL) [82].